Fibroblast growth factors, their receptors and signaling

C J Powers, S W McLeskey and A Wellstein

School of Nursing, Department of Pharmacology, Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA

(Requests for offprints should be addressed to A Wellstein, Georgetown University Medical Center, Lombardi Cancer Center NRB Room E311A, 3920 Reservoir Road, Washington DC 2007, USA; Email: wellstea@gunet.georgetown.edu)

Abstract

Fibroblast growth factors (FGFs) are small polypeptide growth factors, all of whom share in common certain structural characteristics, and most of whom bind heparin avidly. Many FGFs contain signal peptides for secretion and are secreted into the extracellular environment, where they can bind to the heparan-like glycosaminoglycans (HLGAGs) of the extracellular matrix (ECM). From this reservoir, FGFs may act directly on target cells, or they can be released through digestion of the ECM or the activity of a carrier protein, a secreted FGF binding protein. FGFs bind specific receptor tyrosine kinases in the context of HLGAGs and this binding induces receptor dimerization and activation, ultimately resulting in the activation of various signal transduction cascades. Some FGFs are potent angiogenic factors and most play important roles in embryonic development and wound healing. FGF signaling also appears to play a role in tumor growth and angiogenesis, and autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers to a hormone-independent state.

Introduction

The pathogenesis of tumor growth results from the disregulation of the normal mechanisms for cellular homeostasis in the context of the larger multicellular organism. Indeed, neoplasia by its very definition refers to cellular growth heedless to the signals provided by other, non-neoplastic cells that would normally maintain the balance of cellular proliferation and death. Consequently, an understanding of the signaling pathways important for regulating homeostasis will be necessary in order to understand how disregulation of such pathways may contribute to tumorigenesis. Such an understanding will also be necessary for the rational design of therapeutics targeting these signaling pathways.

Fibroblast growth factors (FGFs) and the FGF signaling pathway appear to play significant roles not only in normal development and wound healing, but also in tumor development and progression. The FGF signaling pathway has been the subject of intense investigation in light of its interaction with the heparan-like glycosaminoglycans (HLGAGs) of the extracellular matrix (ECM), as well as its potential role in the progression of some cancers from a hormone-dependent to a hormone-independent growth phenotype. However, there remain a number of unresolved issues regarding how some FGFs are released from the cells that produce them or from the ECM to which they are bound in order to act on their target cells. A clearer understanding of the mechanism by which FGF signaling is regulated and how this signaling contributes to embryonic development, wound healing and tumor growth will facilitate the development of cancer therapies to target this signaling pathway.

The FGF family of polypeptide growth factors

To date, twenty distinct FGFs have been discovered, numbered consecutively from 1 to 20. FGFs induce mitogenic, chemotactic and angiogenic activity in cells of mesodermal and neuroectodermal origin (Basilico & Moscatelli 1992). Defining features of the FGF family are a strong affinity for heparin and HLGAGs (Burgess & Maciag 1989), as well as a central core of 140 amino acids that is highly homologous between different family members. This central core folds into twelve antiparallel β-strands that together form a cylindrical barrel closed by the more variable amino- and carboxy-terminal stretches (Ago et al. 1991, Zhang et al. 1991). Interestingly, this structure is
### Table 1 Characteristics of the members of the FGF family

<table>
<thead>
<tr>
<th>Name</th>
<th>Synonym(s)</th>
<th>Signaling through high-affinity receptors†</th>
<th>Comments*</th>
</tr>
</thead>
<tbody>
<tr>
<td>FGF-1</td>
<td>Acidic FGF, aFGF</td>
<td>FGF-R-1, IIb &amp; IIc; FGF-R-2, IIb &amp; IIc; FGF-R-3, IIb &amp; IIc; FGF-R-4</td>
<td>1 mRNA form, no signal sequence, nuclear localization motif</td>
</tr>
<tr>
<td>FGF-2</td>
<td>Basic FGF, bFGF</td>
<td>FGF-R-1, IIb &amp; IIc; FGF-R-2, IIc; FGF-R-3, IIc; FGF-R-4</td>
<td>4 protein isoforms through the use of alternate start codons, no signal sequence, some isoforms have nuclear localization motifs</td>
</tr>
<tr>
<td>FGF-3</td>
<td>Int-2</td>
<td>FGF-R-1, IIb; FGF-R-2, IIb</td>
<td>Site of MMTV integration in mouse genome, signal sequence, nuclear localization motif</td>
</tr>
<tr>
<td>FGF-4</td>
<td>kFGF, kaposi FGF, hst-1</td>
<td>FGF-R-1, IIc; FGF-R-2, IIc; FGF-R-3, IIc; FGF-R-4</td>
<td>Identified by screening stomach tumors and Kaposi’s sarcoma, signal sequence</td>
</tr>
<tr>
<td>FGF-5</td>
<td></td>
<td>FGF-R-1, IIc; FGF-R-2, IIc</td>
<td>Signal sequence</td>
</tr>
<tr>
<td>FGF-6</td>
<td>hst-2</td>
<td>FGF-R-1, IIc; FGF-R-2, IIc, FGF-R-4</td>
<td>Signal sequence</td>
</tr>
<tr>
<td>FGF-7</td>
<td>KGF</td>
<td>FGF-R-2, IIb</td>
<td>Specific for epithelial cells, signal sequence</td>
</tr>
<tr>
<td>FGF-8</td>
<td>AIGF</td>
<td>FGF-R-1,‡ FGF-R-2, IIc; FGF-R-3, IIc; FGF-R-4</td>
<td>7 isoforms, all with signal sequences</td>
</tr>
<tr>
<td>FGF-9</td>
<td>GAF</td>
<td>FGF-R-2, IIc; FGF-R-3, IIb &amp; IIc, FGF-R-4</td>
<td>No signal sequence, not angiogenic</td>
</tr>
<tr>
<td>FGF-10</td>
<td>KGF-2</td>
<td>FGF-R-1, IIb; FGF-R-2, IIb§</td>
<td>Signal sequence, similar in structure and function to FGF-7</td>
</tr>
<tr>
<td>FGFs 11–14</td>
<td>FGFs</td>
<td>Unknown?</td>
<td>All contain nuclear localization motifs, none contains signal sequence</td>
</tr>
<tr>
<td>FGF-15</td>
<td></td>
<td>Unknown?</td>
<td>Gene is activated by E2A-Pbx1</td>
</tr>
<tr>
<td>FGFs 16–19</td>
<td>FGFs</td>
<td>FGF-17; FGF-1, IIc; FGF-2, IIc¶</td>
<td>All have signal sequence</td>
</tr>
<tr>
<td>FGF-20</td>
<td>XFGF-20</td>
<td>Unknown?</td>
<td>Sequence homology to FGF-9</td>
</tr>
</tbody>
</table>

*Referenced in text. †From Ornitz et al. (1996), except where stated; ‡From Koga et al. (1995); §From Miralles et al. (1999); ¶From Xu et al. (1999).

The presence of a nuclear localization motif appears to be important for FGF-1-induced mitogenesis and removal has been shown to abrogate FGF-1’s mitogenic effect (Imamura et al. 1990), whereas replacement of the nuclear localization motif with that of yeast histone 2B restores FGF-1’s activity. This modular nature of the FGF-1 nuclear localization signal is consistent with the three-dimensional model of the FGF β-barrel, as this amino-terminal region does not participate in the formation of the β-barrel itself (Zhu et al. 1991). FGF-1 has also been shown to stimulate DNA synthesis without signaling through a cell-surface FGF receptor (Wiedlocha et al. 1994), suggesting that the nuclear localization signal may allow FGF-1 to act through an intracrine mechanism. However, the nuclear translocation motif, specifically lysine and leucine residues within it, may actually promote the mitogenic capacity of FGF-1 by stabilizing the FGF-1 receptor binding domain, not through nuclear translocation (Luo et al. 1996). The amino terminus...
of FGF-1 is acetylated in mammalian cells (Crabb et al. 1986); however, as recombinant FGF-1 is equally mitogenic as that produced in mammalian or yeast systems (Jaye et al. 1987), this acetylation is probably not relevant for FGF-1 activity.

**FGF-2 (basic FGF)**

The 18-kDa form of FGF-2 has a 55% sequence identity with FGF-1 (Bohlen et al. 1985, Gimenez-Gallego et al. 1985). Four different FGF-2 polypeptides can be formed from the one fgf-2 gene: in addition to the 18-kDa form, 22.5-, 23.1- and 24.2-kDa forms have also been identified (Florkiewicz & Sommer 1989). The 18-kDa form is a result of translational initiation at the 5′ AUG start codon, while the others are a result of translation beginning at upstream, in-frame, CUG codons (Florkiewicz & Sommer 1989, Prats et al. 1989), thus the larger forms are co-linear amino-terminal extensions of the 18-kDa form. This situation is similar to that of the myc proto-oncogene, which can also use alternate non-AUG codons for translational initiation (Hann et al. 1988).

Like FGF-1, FGF-2 does not contain a signal sequence for secretion. In addition, a nuclear localization sequence has been identified upstream of the AUG start codon (Bugler et al. 1991), and larger forms of FGF-2 associate with the nucleus. However, the role of nuclear localization in the activity of FGF-2 remains unclear.

FGF-2 contains four cysteine residues at amino acids 26, 70, 88 and 93. While the cysteines at 26 and 93 are conserved, those at 70 and 88 are absent or located elsewhere in other FGFs (Arakawa et al. 1989). Mutation of all four cysteines to serines results in a protein with the same secondary structure and equally mitogenic for 3T3 cells as the wild-type FGF-2 (Fox et al. 1988), suggesting that the formation of disulfide bridges is not important for the secondary structure and mitogenic activity of FGF-2 (Arakawa et al. 1989).

It has also been observed that FGF-2 is a substrate for phosphorylation by protein kinase C (PKC) and protein kinase A (PKA). PKC phosphorylates FGF-2 at Ser64; however this has no effect on biological activity, heparin-binding capacity or receptor-binding capacity (Feige & Baird 1989). On the other hand, PKA phosphorylates FGF-2 at Thr112 in the FGF receptor binding domain, resulting in 3- to 8-fold better binding (Feige & Baird 1989b). It is unclear how phosphorylation of FGF-2 is regulated and what physiological role this may have for FGF-2 activity.

**FGF-3 (Int-2)**

FGF-3 is expressed primarily during development (Basilico & Moscatelli 1992) but it was first identified as an activated gene in mouse mammary carcinogenesis. fgf-3 was found to be a site in which the mouse mammary tumor virus (MMTV) often (50%) integrates and was named int-2 (Dickson et al. 1984). Normally the FGF-3 promoter is silent in adult animals, but the long terminal repeat (LTR) of the proviral MMTV is a strong activator of the FGF-3 promoter (Grimm & Nordeen 1998), driving expression of a gene more properly expressed during development. Insertion of the provirus rarely occurs in the coding regions of fgf-3 (Morris & Dutra 1997).

In the mouse, six different transcripts of the fgf-3 gene are produced, all predicted to code for the same 245 amino acid protein based on a defined AUG start codon (Acland et al. 1990). The human fgf-3 gene codes for a 239 amino acid protein (Brookes et al. 1989a) with 44% amino acid homology to FGF-2 in the core region (Dickson & Peters 1987). However, unlike FGF-2, FGF-3 has a defined amino-terminal signal sequence for secretion and also a C-terminal nuclear localization sequence (Antoine et al. 1997). As with FGF-2, translational initiation at CUG codons 5′ to the AUG start codon results in larger polypeptide forms, often containing additional nuclear localization sequences (Kiefer et al. 1994). Consequently, localization of FGF-3 to the nucleus or to the secretory pathway is determined by competition between the signal sequence and the nuclear localization sequences (Kiefer et al. 1994). The role of localization to the nucleus or the secretory pathway in FGF-3 activity remains uncharacterized. However, exclusive production of a mutant lacking the signal sequence, yet containing the amino-terminal nuclear localization sequence, results in accumulation in the nucleus and inhibition of DNA synthesis and cell proliferation (Kiefer & Dickson 1995).

**FGF-4 (hst-1/kFGF)**

fgf-4 was identified by the screening of human stomach tumors and samples of Kaposi’s sarcoma for genes capable of transforming 3T3 fibroblasts (Sakamoto et al. 1986, Delli Bovi & Basilico 1987). Initially, there were thought to be two different genes responsible for this activity, hst and the KS oncogene, but, based on homology to each other and to other fgfs, they were found to be one gene, fgf-4 (Delli Bovi et al. 1987, Yoshida et al. 1987). As with fgf-3, expression of murine fgf-4 has been shown to be upregulated by insertion of the MMTV provirus. In fact, because both murine genes are located within twenty kilobases of each other it has been suggested that they have evolved as a result of tandem duplication of a common ancestral gene (Brookes et al. 1989b). Human fgf-4 codes for a 206 amino acid protein with a 42% homology in the core regions to FGF-2 (Taira et al. 1987). Newly translated FGF-4 contains a signal sequence as well as an N-glycosylation site (Miyagawa et al. 1991). Deletion of the signal sequence suppresses fgf-4’s ability to transform 3T3 cells suggesting that FGF-4 acts predominantly through cell surface receptors (Talarico &
Basilico 1991). On the other hand, not only has the N-glycosylation site been shown to be irrelevant for FGF-4-induced angiogenesis (Yoshida et al. 1994), but overexpression of a mutant form of the protein which cannot be glycosylated results in the production of a more active factor, suggesting that glycosylation may actually negatively regulate FGF-4 activity (Bellosta et al. 1993).

**FGF-5**

fgf-5 was originally identified by screening genes recovered from human tumor cell lines for their ability to promote 3T3 fibroblast growth in the absence of serum growth factors (Zhan et al. 1987). The FGF-5 protein is 267 amino acids long and has 40% and 50% homology in the core region to FGF-1 and -2 respectively (Zhan et al. 1988, Bates et al. 1991, Goldfarb et al. 1991). FGF-5 is also secreted as a glycoprotein (Bates et al. 1991), although glycosylation has not been shown to potentiate its activity (Clements et al. 1993).

**FGF-6 (hst-2)**

Unlike most other early fgf genes, which were identified by screening tumor genes for a mitogenic effect on 3T3 fibroblasts, fgf-6 was first isolated based on its sequence similarity to fgf-4 (Sakamoto et al. 1988, Marics et al. 1989). FGF-6 is a 198 amino acid protein containing a signal sequence (Iida et al. 1992) and glycosylation site. However, glycosylation does not seem to be important for the FGF-6-stimulated [3H]thymidine incorporation in 3T3 fibroblasts (Pizette et al. 1991).

**FGF-7 (KGF)**

FGF-7 was initially isolated as a growth factor specific for epithelial cells from the conditioned medium of a human fibroblast cell line and named keratinocyte growth factor (KGF) (Rubin et al. 1989). Because FGF-7 is produced by fibroblasts yet is only mitogenic for epithelial cells and not for fibroblasts or endothelial cells (Rubin et al. 1989), it has been suggested that FGF-7 is a unique stromal mediator of epithelial proliferation (Finch et al. 1989). fgf-7 codes for a 194 amino acid protein containing a signal sequence and an N-linked glycosylation site (Aaronson et al. 1991).

**FGF-8 (AIGF)**

FGF-8 was initially identified as androgen-induced growth factor (AIGF) found in the conditioned medium of the androgen-dependent mouse mammary carcinoma cell line SC-3 (Tanaka et al. 1992). FGF-8 was found to be expressed and secreted in response to treatment with androgens in both the human breast cancer cell line MDA-MB-231 and the SC-3 cell lines (Payson et al. 1996). fgf-8 was also identified as a frequently activated gene in tumors from MMTV-infected Wnt-1 transgenic mice, much like fgf-3 and fgf-4 (MacArthur et al. 1995b). Murine fgf-8 contains six exons and alternate splicing has been shown to result in at least seven isoforms with different efficiencies of colony formation in soft agar (MacArthur et al. 1995a). These isoforms differ at their amino-termini; however, the signal sequence is not altered. Regulation of isoform production has been proposed as a post-transcriptional mechanism for control of FGF-8 activity (MacArthur et al. 1995a).

**FGF-9 (GAF)**

FGF-9 was originally purified from the conditioned medium of the glial cell line NMC-G1 and, based on its activity, named glia-activating factor (GAF) (Miyamoto et al. 1993). FGF-9 is mitogenic for glial cells and fibroblasts, but has no effect on endothelial cells. fgf-9 codes for a 208 amino acid protein which does not contain an amino-terminal signal sequence, like FGF-1 and FGF-2. Nevertheless, FGF-9 is still efficiently secreted, suggesting that it utilizes an alternate ER-Golgi-independent pathway for secretion.

**FGF-10**

fgf-10 was initially identified from rat embryos by homology-based PCR (Yamasaki et al. 1996). In fact, with the exception of FGF-15, all FGFs beyond FGF-9 have been isolated based on sequence information rather than the isolation of growth-promoting activity from tumors or tumor cell lines. FGF-10 is a 208 amino acid glycoprotein with a signal sequence (Emoto et al. 1997). FGF-10 has a high protein sequence similarity to FGF-7 and they are both mitogenic for keratinocytes (Emoto et al. 1997). Unlike FGF-7, however, FGF-10 in high concentrations is capable of stimulating fibroblasts (Igarashi et al. 1998). FGF-10 also has a higher affinity for heparin than FGF-7 (Lu et al. 1999) which may, in part, explain both why FGF-10 is associated with the cell matrix while FGF-7 is freely secreted, and why heparin inhibits the activity of FGF-7 yet potentiates FGF-10 (Igarashi et al. 1998). Like FGF-7, FGF-10 is expressed in stromal cells, especially those of muscle origin (Lu et al. 1999).

**FGF-11, -12, -13, -14 (FHFs)**

The FGF homology factors (FHFs) were identified together by random cDNA sequencing, database searches and degenerate PCR of human retinal tissues (Smallwood et al. 1996). The FHFs share between 58% and 71% amino acid identity between themselves, yet have less than 30% amino acid identity with other FGFs (Smallwood et al. 1996). This divergence is not surprising, considering that the early FGFs...
are generally quite distinct from each other at the amino acid level, perhaps because, with the exception of FGF-8, they were isolated based on activity rather than sequence homology. FGF-11, -12, -13, -14 all contain nuclear localization signals and FGF-11 has been definitely identified as accumulating in the nucleus; however, none has been shown to possess a signal sequence for secretion (Smallwood et al. 1996). A novel isoform of FGF-13 by alternate splicing of the first exon has been shown to result in a protein with a unique amino-terminus (Munoz-Sanjuan et al. 1999); however, any effect this may have on activity has not yet been determined.

FGF-15

fgf-15 was identified as a downstream target of E2A-Pbx1, a homeodomain transcription factor fused by the t(1;19) chromosomal translocation in pre-B cell leukemias to the activation domain of the basic helix-loop-helix (bHLH) transcription factor E2A (McWhitter et al. 1997). Because E2A-Pbx1 is thought to aberrantly activate genes normally regulated by Pbx1 during development, fgf-15 is thought to play some role during embryogenesis.

FGF-16, -17, -18, -19

As with ffg-10, the cDNAs for these FGFs were isolated from rat tissues by homology-based PCR (Hoshikawa et al. 1998, Miyake et al. 1998, Ohbayashi et al. 1998, Nishimura et al. 1999). These cDNAs code for proteins which range in size from 207 to 216 amino acids and all are thought to play some, as yet uncharacterized, role in development.

FGF-20 (XFGF-20)

Recently, the latest member of the FGF family, FGF-20, has been identified by degenerate PCR-based screening of a Xenopus cDNA library with a probe based on the mammalian FGF-9 (Koga et al. 1999). The FGF-20 cDNA contains a single open reading frame coding for a 208 amino acid protein. Because FGF-20 is expressed in early stages of embryonic development, as determined by RT-PCR, and because overexpression of FGF-20 mRNA results in abnormal gastrulation, it is likely that FGF-20 plays a role in development.

FGF secretion

It is clear that most FGFs act extracellularly, not only because family members are present in the extracellular matrix, most noticeably FGF-2 (DiMario et al. 1989), but also because of their activity through high-affinity extracellular receptors (Safran et al. 1990). It is puzzling then that three of the FGF family members, FGF-1, FGF-2 and FGF-9, lack classical leader sequences. The leader sequence is a stretch of hydrophobic amino acids located at the amino terminus of newly synthesized polypeptide chains which plays a key role in the classical polypeptide secretion pathway (Blobel 1980). The leader sequence is recognized by a signal recognition particle (SRP) which halts translation and trafficks the translation complex to the ER. At the ER, translation of the polypeptide resumes with vectorial transport of the nascent polypeptide chain into the ER lumen. Secretory proteins can be completely released into the ER lumen while transmembrane proteins become anchored to the membrane by an additional hydrophobic sequence. From the ER, proteins destined for secretion are transported to the Golgi apparatus and are eventually packaged into vesicles for secretion from the cell surface.

Because the large (greater than 18 kDa) forms of FGF-2 contain different 5′ sequences (due to the use of upsteam, non-AUG codons for translational initiation), Florkiewicz & Sommer (1989) have hypothesized that these larger forms of FGF-2 may contain signal sequences in their amino-terminal extensions. However, this hypothesis is inconsistent with the observation that, while the 18-kDa form remains cytoplasmic, the larger forms associate with the nucleus instead of with secretory vesicles (Renko et al. 1990). The nuclear trafficking of larger forms of FGF-2 is due to the addition of a nuclear localization signal in the 37 amino acids upstream of the AUG start site (Bugler et al. 1991), and it is now clear that no FGF-2 species contain classical leader sequences. The fact that three of the FGF family members, FGF-1, FGF-2 and FGF-9, lack classical leader sequences implies that they may be transported to the extracellular space by some other mechanism.

There have been various mechanisms proposed for the release of FGF family members lacking leader sequences. Mechanical damage has been proposed as one such mechanism for release of biologically active FGF-2 from endothelial cells (McNeil et al. 1989). While cell damage may provide a physiologically appealing mechanism for FGF-2 release in wound repair, it could hardly serve as a regulatable mechanism for FGF-2 release during development. Heat-shock has been found to trigger FGF-1 release; unfortunately the released form of FGF-1 is neither mitogenic nor does it bind heparin (Jackson et al. 1992). However, FGF-1 release following heat-shock is inhibited by cycloheximide and potentiated by treatment with brefeldin A, a Golgi inhibitor (Jackson et al. 1995), implying that new protein synthesis is required, perhaps of some chaperone protein(s), which facilitates the transport of FGF-1 from a cytoplasmic pool separate from the Golgi-derived secretory pool. Components of this FGF-1 chaperone complex may include synaptotagmin-1 and the calcium-binding protein S100A13. Synaptotagmin-1 is a 65-kDa vesicular protein that acts as a calcium sensor for neurotransmitter release (Kelly 1995). LaVallee et al. (1998) have shown that a
40-kDa proteolytic fragment of synaptotagmin is released along with FGF-1 following heat-shock and Tarantini et al. (1998) have shown that expression of an antisense synaptotagmin-1 gene represses this release. S100A13, another component of this release mechanism, binds the anti-inflammatory compound amlexanox. Carreira et al. (1998) have shown that amlexanox represses the heat-shock-induced release of FGF-1 and synaptotagmin-1 in a dose-dependent manner. Together, this is consistent with a model in which the FGF-1: synaptotagmin-1 (and perhaps also S100A13) complex at the cytosolic face of exocytotic vesicles trafficks to the cytoplasmic membrane and from there to the extracellular space in response to heat-shock and perhaps some other as yet unidentified stimulus.

By use of a phagokinetic assay (Albrecht-Buehler 1977), Mignatti et al. (1992) has demonstrated two characteristics of FGF-2 secretion. The migration of individual 3T3 cells in the phagokinetic assay is enhanced by a calcium ionophore, yet is not affected by drugs that block ER-Golgi-mediated secretion. This implies that FGF-2 is released by an ER-Golgi-independent mechanism. In addition, the motility of individual cells is inhibited by antibodies to FGF-2 added to the culture medium, which presumably block the extracellular ligand-receptor interaction (Mignatti et al. 1991). If FGF-2 were signaling by an intracrine mechanism to promote cell migration, this migration should not be affected by the extracellular antibody. Consequently, this implies that FGF-2 acts in an autocrine, not intracrine, fashion to promote fibroblast motility.

In the classical secretion pathway, the signal sequence is cleaved from the polypeptide in the ER; consequently, if there were some other domain of FGF that fulfills the role of the signal sequence it might be reasonable to expect that this sequence may be removed during transport as well. Amino-terminal degradation has been found to occur with FGF-2, by comparing the predicted cDNA sequence to that of the secreted protein. However, the portion of FGF-2 removed, while being slightly hydrophobic, does not contain a known signal sequence motif (Klagsbrun et al. 1987). The situation is different with FGF-9, as almost the full-length FGF-9 protein is secreted from COS cells following transfection of the FGF-9 cDNA (Miyamoto et al. 1993). Using amino- and carboxy-terminal peptide antibodies as well as amino-terminal sequence analysis, it has been determined that only the amino-terminal methionine of FGF-9 is cleaved between translation and secretion. This provides still further evidence that secretion of FGF family members lacking classical leader sequences is through some novel secretory pathway that is probably independent of the ER and the Golgi apparatus.

It is possible that FGF family members lacking leader sequences may be secreted by the same secretory pathway as IL-1β, which also lacks a signal sequence. Support for this hypothesis comes from the fact that neither IL-1β nor FGF-2 are found in cytoplasmic vesicles (Rubartelli et al. 1990) and because IL-1β has approximately a 30% homology with FGF-1 (Jaye et al. 1986). Rubartelli et al. (1990) have suggested that IL-1β may avoid the classical secretory pathway for reasons that are applicable to the FGFs as well: first, the thiol groups in IL-1β and the FGFs may require a reducing environment in order to be functional and must therefore avoid the oxidative environment in the ER, and secondly, perhaps IL-1β and the FGFs utilize an alternative secretory pathway in order to compartmentalize ligands from receptors and avoid intracrine signaling. However, similarities between IL-1β and the FGFs do not account for all the possible pathways of FGF secretion. IL-1β secretion is not inhibited by cycloheximide while FGF-1 secretion following heat-shock is dependent on new protein synthesis and the synaptotagmin-1:S100A13 complex.

The secretion of FGF-3 provides a counter example to the secretory pathways of FGF-1, -2 and -9. Like many other FGF family members FGF-3 has a leader sequence; however, it is inefficiently secreted compared with FGF-4 and -5. FGF-3 accumulates in the Golgi apparatus after entering the secretory pathway and undergoing primary glycosylation. Kiefer et al. (1993) have proposed that FGF-3 is slowly secreted because of the unique character of its amino-terminal glycosylation site, which may sequester FGF-3 in the Golgi apparatus. Amino-terminal glycosylation is important for cell-surface transport (Guan et al. 1985) and substitution of the FGF-3 amino-terminus with that of FGF-5 resulted in efficient secretion of the hybrid protein. However, the reader should recall that, like FGF-2, there is a nuclear localization sequence 5’ to the AUG start codon in FGF-3. Consequently, the improvement that Kiefer and coworkers observed may be due to altered competition between secretion and nuclear localization rather than the glycosylation effect resulting in Golgi retention.

### Physical interactions between FGFs and heparin

While FGF family members can be quite divergent in their amino acid sequences and expression, binding to heparin and HLGAGs is a defining feature of the family. Armelin (1973) and Gospodarowicz (1974) were the first to isolate FGF-1 and -2. They partially purified a growth-promoting fraction of bovine pituitary extracts, containing both FGF-1 and -2, which was capable of stimulating [H]thymidine uptake in 3T3 cells. Purer preparations of FGF-1 and -2 were made by utilizing the growth factors’ intrinsic affinity for heparin binding. FGF-1 was found to elute from a heparin-Sepharose column with 1 M NaCl (Maciag et al. 1984, Thomas et al. 1984) while FGF-2 could be eluted with 1.5 M NaCl (Esch et al. 1985).

The heparin polymer is a disaccharide chain composed of alternating l-iduronic acid (Idu) and d-glucosamine (GlcN)
moieties joined by α (1-4) linkages (Faham et al. 1996). Each disaccharide unit may contain a total of three sulfate groups: one at the 2-hydroxy group of Idu, one at the 2-amino group of GlcN, and one at the 6-hydroxyl group of GlcN. These sulfate groups impart a strong negative charge to the heparin chain. The glycosaminoglycan heparan sulfate is structurally similar to heparin; however, it also contains d-glucuronic acid moieties and is not as fully sulfated, resulting in less of a negative charge.

The strong binding to heparin requires the existence of specific heparin-binding domains in FGFs. Extensive research has gone into identifying these heparin-binding sites at both the functional level and the molecular level. Using reductive methylation, Harper and Lobb (1988) identified Lys109 as playing an important role in FGF-1 binding to heparin. Lobb (1988) determined that thrombin was able specifically to inhibit FGF-1’s binding to heparin, but not that of FGF-2, by cleaving the protein between Arg122 and Thr123. This cleavage removed eighteen carboxy-terminal amino acids, suggesting that the heparin-binding activity of FGF-1 resides in the carboxy-terminus of the full-length protein. There are three putative heparin-binding domains based on similarity to motifs proposed by Jackson et al. (1991). Site directed mutagenesis of these domains reveals that only the carboxy-terminal site between amino acids 122-137 is actually involved in heparin binding (Wong et al. 1995). Together these results indicate that the functional domain for heparin binding is dependent on residues at the carboxy terminus of FGF-1, probably between amino acids 122-137.

Efforts to identify the heparin-binding sites of FGF-2 resulted in the initial determination of two sites as ascertained by stoichiometric analysis of heparin-FGF-2 mixtures (Arakawa et al. 1994). Baird et al. (1988) characterized two functional heparin-binding domains in FGF-2 through the use of peptide blocking studies and localized these domains to amino acids 24-68 and 106-115. Not only did peptides corresponding to these two sequences inhibit binding of [125]FGF-2 to immobilized heparin, the peptides themselves were also capable of binding [1H]heparin. More recently, Faham et al. (1996) have used crystal structures of heparin-derived tetra- and hexasaccharides with FGF-2. Their paper also identified two sites of interaction, although the amino acids involved were not arranged consecutively in the primary structure of the polypeptide chain, as was the case in the peptide blocking studies of Baird. Instead, the binding sites were composed of groups of basic amino acids brought together by the secondary structure of the folded polypeptide. It is difficult to reconcile these two reports except to suppose that, while small peptides may contain amino acids capable of binding heparin, the functional heparin-binding sites of the larger protein can only be ascertained by an analysis of its secondary structure in the context of heparin binding.

This discussion of heparin binding now leads us to a more relevant question: is heparin binding just a convenient method for purification of FGFs or is it essential for the function of these growth factors? An interaction between FGF-2 and the ECM was suggested by the fact that FGF-2 regulates the interaction of bovine epithelial lens (BEL) cells with their ECM in vitro (Tassin et al. 1983). Treatment with FGF-2 alters the morphology of BEL cells by decreasing their production of ECM components such as laminin and fibronectin, such that they assume a more rounded shape because there are fewer sites of attachment. If FGFs were a component of the ECM itself we could explain this observation as part of a negative feedback loop which ordinarily keeps production of the ECM in check.

Jeanny et al. (1987) were the first to describe FGF-2 in the ECM and found that [125]FGF-1 and -2 bound specifically to the basement membranes in the mouse embryonic eye. Vlodavsky et al. (1987) showed that endothelial cells synthesize FGF-2 which is then deposited and sequestered in the subendothelial ECM, a major component of which is heparan sulfate proteoglycan. It was also determined that this binding of FGF-2 to the basement membrane was specific to HLGAGs and not other basement membrane components such as laminin or collagen type IV (Vigny et al. 1988). Folkman et al. (1987) hypothesized that the interaction with heparin is representative of an in vivo affinity of FGFs for heparin sulfate proteoglycans, and furthermore, that the storage of FGFs in the basement membrane may be a mechanism for regulating their accessibility to vascular endothelium. Neovascularization may therefore be the result of the release of angiogenic factors from their storage in the basement membrane.

**Functional consequences of FGF-heparin binding**

The binding of the FGFs to heparin or HLGAGs may serve two physiologically relevant goals: the protection of the FGFs from degradation and the creation of a local reservoir of growth factors. Early studies of the binding of FGF-1 and -2 to heparin showed that this interaction protected the growth factors from acid and heat (Gospodarowicz & Cheng 1986), to which they are extremely sensitive, and from degradation by aprotinin-sensitive proteases (Damon et al. 1989). However, these conclusions are obscured by the fact that in these studies, biological activity was used as an indicator of protection of FGFs instead of an analysis of the remaining protein itself. Because heparin alone did not have any biological activity in these studies, the conclusion was made that any mitogenic effect must be due to the FGFs themselves. However, a synergistic effect on mitogenicity by heparin with the FGFs may also have explained the observed protection of biological activity. Later studies did make this distinction and found that heparin or HLGAGs protect the
FGF-1 protein itself from proteolysis by thrombin (Lobb 1988), and the FGF-2 protein from trypsin (Sommer & Rifkin 1989) and plasmin (Saksela et al. 1988). Thus, one effect of HLGAG binding in vivo seems to be protection from circulating proteases.

The role of FGFs in development provides a clear example of the second physiologically relevant goal of HLGAG binding: the creation of a local reservoir of growth factors. This local reservoir allows for a strict spatial regulation of FGF signaling, as FGFs can only signal to those cells in contact with the ECM. In limb development the creation and maintenance of a concentration gradient of FGFs is crucial for the function of the apical ectodermal ridge (AER) in promoting limb outgrowth. That there must be a focal concentration of FGFs is demonstrated by the fact that beads soaked in FGFs can replace the AER, while exposure of the entire embryo to FGFs will not result in additional limb development (Cohn et al. 1995). FGFs must be localized to a particular population of cells in order to be useful in organized development and prevention of diffusion elsewhere can be achieved by the binding of FGFs to HLGAGs in the ECM. In addition, the regulated expression of cell surface HLGAGs could provide a mechanism for the regulated localization of FGFs (Gould et al. 1995).

The creation of a local reservoir of FGFs not only implies that FGF signaling may be spatially regulated, but also that a large supply of FGFs may be mobilized from this reservoir. In fact, the process of mobilizing FGFs from the ECM may itself be extensively regulated, allowing an indirect control of FGF signaling through regulation of its mobilization from the ECM to target cell surface receptors. This type of regulation may be particularly important in the formation of new blood vessels, a process that is known to be governed by a variety of positive and negative regulatory factors. That such a large functional reservoir of FGFs exists is clear from the observation that the EC_{50} of FGF-2 for its receptor is approximately 1 ng/ml, while the tissue concentration of FGF-2 has been found to be between 10 and 500 ng/ml (Gospodarowicz 1987). There are currently two known mechanisms for the release of FGFs from this ECM reservoir: enzymatic cleavage of ECM components, by proteases or heparanases, resulting in the release of FGFs, or by the binding to a carrier protein, FGF binding protein (FGF-BP), which can then deliver FGFs to their receptors. We will address both of these mechanisms in greater detail below in the discussion of FGF signaling in cancer.

**FGF receptors**

**Initial characterization of receptors**

It is clear that FGFs produce their mitogenic and angiogenic effects in target cells by signaling through cell-surface, tyrosine kinase receptors. That FGF signaling involves tyrosine phosphorylation was first suggested by a finding that FGF-1 and FGF-2 stimulated tyrosine phosphorylation in 3T3 fibroblasts, as detected by Western blots using phosphotyrosine antibodies (Coughlin et al. 1988). Based on these findings, it was proposed that the mitogenic effect of FGFs on fibroblasts was elicited, at least in part, by protein modification through tyrosine phosphorylation. The existence of FGF receptors themselves was supported by the early binding studies of Moscatelli (1987), who used [^{125}I]FGF-2 to find a high affinity (K_{D}=20 pM) FGF receptor on the surface of BHK cells. A series of crosslinking studies identified these high affinity sites as proteins between 125 and 160 kDa (Neufeld & Gospodarowicz 1985, 1986, Friessel et al. 1986, Moenner et al. 1986, Blanquet et al. 1989) which could bind both [^{125}I]FGF-1 and [^{125}I]FGF-2.

Isolation from the chicken cDNA of a receptor capable of binding FGF-1 provided valuable information on the structure of the FGF receptor protein (Lee et al. 1989). This first FGF receptor was found to be a transmembrane protein containing three extracellular immunoglobulin (Ig)-like domains (designated IgI, IgII and IgIII), an acidic region between IgI and IgII, a transmembrane domain, and an intracellular tyrosine kinase domain. This protein structure places the FGF receptor in the Ig superfamily of receptors, such as platelet-derived growth factor (PDGF)-α receptor (PDGFαR), PDGFβR and interleukin-1 receptor (IL-1R), which are also receptor tyrosine kinases containing Ig-like domains (Johnson et al. 1990). Cloning of the human FGF receptor (FGFR) genes identified the first two, fgfr-1 and fgfr-2, as fgl and bek (Dionne et al. 1990), both of which were previously identified tyrosine kinase proteins (Kornbluth et al. 1988, Ruta et al. 1989). There are now four known FGF receptors, FGFR-1 through FGFR-4, which share between 55% and 72% homology at the protein level (Johnson & Williams 1993) (see Fig. 1).

**FGFR diversity**

**Requirement for FGFR diversity**

As we have seen, there are many different types of FGFs, and these different proteins have diverse effects (mitogenesis, angiogenesis, chemotaxis, etc.) on diverse target cells (fibroblasts, endothelial cells, keratinocytes, etc.). In order to achieve this kind of diversity, the FGF signaling system demands variation at the level of the receptors. The required diversity is typified with the case of FGF-7, which, unlike FGF-1 and FGF-2, is mitogenic for keratinocytes but not fibroblasts or endothelial cells (Rubin et al. 1989). The difference in cell response to these different FGFs implies that the different cells express different forms of the FGF receptor.
Mechanisms for FGFR diversity

Different forms of the FGF receptor may be expressed in two possible ways: by the expression of splice variants of a given FGFR gene, or by the expression of different FGFR genes themselves (see Fig. 2).

Alternate splicing of the same gene

Through the use of splice variants it is possible for the same FGFR gene to code for a variety of different receptor protein isoforms. This kind of diversity is possible with FGF receptors because of the structure of the respective genes.
Using the FGFR-1 gene as a prototype, the following structural features are found in the mRNA prior to splicing: a 5' non-translated sequence, a hydrophobic signal sequence, the IgI and IgII sequences separated by an "acid box", the 5' end of the IgIII sequence followed by three possible 3' ends of IgIII that are due to alternative splicing, the transmembrane domain, and finally the kinase domain (see Fig. 3). Analysis of the FGFR genes reveals that \textit{fgfr}-1, \textit{fgfr}-2, and \textit{fgfr}-3 have a remarkable conservation of the arrangement of intron/exon boundaries (Ornitz \textit{et al.} 1996). Different exon usage allows the translation of proteins which may be prematurely truncated, lack Ig-like domains, or utilize different coding regions for the same Ig-like domains (see Fig. 2). For example, variations in splicing have been shown to result in secreted receptors which are truncated after either IgI or IgIII by the introduction of early stop codons (Johnson \textit{et al.} 1993). Alternatively, differential splicing may result in the loss of IgI (Johnson \textit{et al.} 1990), which, while not shown to significantly alter FGF-1 and FGF-2 binding to FGFR-1 (Johnson \& Williams 1993), may explain the differences in receptor sizes found in the initial crosslinking studies described above. Finally, variations in splice site usage may result in the coding for one of three possible IgIII domains.

One of the most important mechanisms by which FGFR receptors determine specificity for different FGFs is by alternate exon usage of the IgIII forms. The exons coding for the three possible IgIII domains, designated IgIIla, IgIIlb and IgIIlc, are situated continuously and in the same order in \textit{fgfr}-1, \textit{fgfr}-2 (Johnson \textit{et al.} 1991) and \textit{fgfr}-3 (Chellaiah \textit{et al.} 1994). The \textit{fgfr}-4 gene is unique in that there is only one possible form of its IgIII domain (Vainikka \textit{et al.} 1992). The IgIIla splice variant codes for a truncated protein which, as it is secreted and is not a transmembrane protein, cannot independently transduce an extracellular signal, although it may act to sequester released FGFs and inhibit FGF signaling. However, differential expression of IgIIlb and IgIIlc is very important for determining FGF signaling specificity. Interestingly, the expression of FGRF-2 isoforms of IgIIlb and IgIIlc is restricted to cells of epithelial and mesenchymal lineages respectively (Orr-Urteger \textit{et al.} 1993, Yan \textit{et al.} 1993, Alarid \textit{et al.} 1994). Because FGF-7 is known to bind FGFR-2(IIlb) but not FGFR-2(IIlc) (Ornitz \textit{et al.} 1996), this may explain the selectivity of FGF-7 for keratinocytes over fibroblasts as due to the expression of these different splice variants.

**Analogous splice variants of different genes**

Because the IgIII domain seems to be so important for specificity of FGF binding, and because the three IgIII domains are more homologous between genes than between each other, one might conclude that the same IgIII domain would confer specificity of binding regardless of which \textit{fgfr} gene is expressed. However, this is not the case. For example, FGF-7 binds FGFR-2(IIlb) but not FGFR-1(IIlb) or FGFR-3(IIlb), despite the fact that all three receptors have the same IgIIlb splice variant (Ornitz \textit{et al.} 1996). This implies that there are other receptor domains besides IgIII which confer binding specificity, and these domains differ between the different \textit{fgfr} genes.

The use of both mechanisms for receptor diversity, different IgIII splice variants of the same gene and different genes coding for the same IgIII splice variant, allows for seven different receptor possibilities (3 receptor genes × 2 splice variants [IIlb and IIlc] each=6 possibilities). Ornitz \textit{et al.} (1996) determined the specificity of different FGFs for different receptor isoforms by overexpressing these isoforms in Baf3 cells, which do not normally express FGFRs, and assaying for [\textit{H}]thyridine incorporation in these cells following treatment with different FGFs (see Table 2). Their results convincingly show that diversity in FGF signaling is achieved by different FGFs binding to different FGFR splice variants and different \textit{fgfr} gene products.

**Role of FGF-heparin interaction in FGFR activation**

As part of the search for molecules involved in FGF signaling, low and high affinity binding sites for FGF were found on the surface of cells in culture. As mentioned above, Moscatelli (1987) performed a Scatchard analysis of the binding of [\textit{125I}]FGF-2 to baby hamster kidney (BHK) cells and found two binding sites for FGF: a high affinity binding...
surface HLGAGs could bind [125 I]FGF-2 while mutant CHO expressing a high affinity FGF receptor, FGFR-1, and cell high affinity receptor. 

activator production, an induction mediated by binding to the sites, had no effect on FGF-2 stimulation of plasminogen heparin, such that there was none bound to the low affinity signaling because saturating FGF-2 with exogenous free affinity sites was not physiologically relevant for FGF treatment with heparinase abolished 62% of the low affinity molecules. This conclusion was supported by the fact that represented the binding of FGF to cell surface heparin-like GAGs such as chondroitin sulfate and keratin sulfate, binding to the low affinity sites was competed for by heparin Moscatelli concluded that this low affinity binding (GAGs) such as chondroitin sulfate and keratin sulfate, could be restored by the addition of heparin or heparan sulfate. Lindahl and Hook (1978) had already argued that binding to the HLGAG-deficient mutant CHO cells expressing a high affinity FGF receptor, FGFR-1, and cell surface HLGAGs could bind [125 I]FGF-2 while mutant CHO cells that did not express the cell surface HLGAGs could not, even when they did express FGFR-1. In addition, they found that binding to the HLGAG-deficient mutant CHO cells could be restored by the addition of heparin or heparan sulfate. Lindahl and Hook (1978) had already argued that HLGAGs were capable of inducing a conformational change in proteins to which they bound. Consequently, Yayon et al. (1991) proposed that both free and cell surface HLGAGs were capable of imparting a receptor-compatible conformational shift on FGF-2 and thereby promote FGF-2 binding to its receptor. This model explained Moscatelli’s observation regarding the competition of FGF-2 off the cell-surface HLGAGs with heparin as not being a competition but rather a substitution of one molecule (cell surface HLGAG) capable of facilitating FGFR binding with another molecule (heparin) capable of doing the same thing.

It has also been demonstrated that cell surface HLGAGs not only facilitate binding to FGFR-1, but also to FGFR-2 (Mansukhani et al. 1992), and that this binding facilitates FGF signaling, triggering mitogenesis and angiogenesis (Rapraeger et al. 1991, Aviezer et al. 1994). Based on the above observations Klagsbrun and Baird (1991) proposed a model for the role of cell surface HLGAGs in FGF signaling. First, the HLGAGs recruit FGFs to the cell surface, increasing their concentration and making activation of their receptors more thermodynamically favorable. Secondly, the HLGAGs induce a conformational shift in either FGFs or their receptors such that binding between the two is favored. More recently the thinking has shifted from HLGAGs inducing a conformational shift to their presentation of FGFs in a form more likely to activate their receptors. Ornitz et al. (1992) first proposed that heparin facilitates FGF oligomerization and speculated as to a role this may have in triggering receptor dimerization and activation. Ornitz and coworkers showed that FGF-induced mitogenic activity is heparin-dependent and that heparin is required for FGF-2 binding to FGFR-1 in a cell-free assay. The dynamics of this cell-free assay also allowed Ornitz and coworkers to argue that heparin facilitates FGF oligomerization. Spivak-Kroizman et al. (1994a) supported this argument by showing through isothermal titration calorimetry that FGF-1 forms a 1:1 complex with the extracellular domain of the FGF receptor. The fact that heparin is capable of binding many molecules of FGF also supports the argument that the FGF-1-heparin complex can bind several receptors, resulting in their dimerization and activation. In addition, a synthetic heparin analog, sucrose octasulfate, which binds only one FGF-1 molecule, is capable of blocking FGF receptor dimerization and activation. Consequently, the current understanding of the ability of FGFs to activate their receptors is that they induce receptor dimerization, and that this dimerization is facilitated by HLGAGs.

**FGF receptor dimerization and activation**

FGF receptors, like other receptor tyrosine kinases, transmit extracellular signals to various cytoplasmic signal transduction pathways through tyrosine phosphorylation. Following ligand binding and dimerization, the receptors become capable of phosphorylating specific tyrosine residues on their own and each other’s cytoplasmic tails (Lemmon &
Inhibition of receptor dimerization in the absence of FGF

As ligand binding and subsequent dimerization initially determines receptor activation, in order for signals to be appropriately transmitted a mechanism must be present to prevent FGFR dimerization in the absence of FGF. Two mutually consistent theories have been proposed to explain FGFR dimerization only in the presence of FGF. Kan et al. (1996) have shown that divalent cations and HLGAGs can cooperate to maintain the FGFR in a conformation that restricts dimerization and prevents receptor activation. Wang et al. (1997) identified the sequence that regulates this inhibition as being in the extracellular domain of FGFR between IgII and IgIII from Glu160 to Lys176, a region which promotes receptor self-association. In the proposed model, divalent cations and HLGAGs suppress this region’s intrinsic tendency to promote receptor dimerization. However, binding of FGF to FGFR releases this suppression and can thereby promote receptor dimerization.

Plotnikov et al. (1999) proposed an alternate, though not inconsistent, mechanism to prevent FGFR dimerization in the absence of ligand. There is a region in IgII containing several basic amino acids that is probably important for HLGAG binding to FGFR. Consequently, it may be possible that HLGAGs themselves could cross-link two FGFRs by binding to this region of IgII. However, Plotnikov and coworkers proposed that the acid box, a region between IgI and IgII, is capable of interacting with this basic region of IgII, thereby preventing HLGAG binding. Following FGF binding, this inhibition would be lifted and dimerization could occur. However, as there are some splice variants that lack the acid box yet exhibit no peculiarities in dimerization, this mechanism may not be absolutely necessary.

Solving the HLGAG-FGF-FGFR trimolecular complex

It is important to note that in both of the mechanisms to prevent ligand-independent dimerization described above, different mechanisms are capable of promoting FGFR dimerization. Kan’s and Wang’s model addresses an intrinsic tendency for FGFR dimerization mediated by a sequence between IgI and IgII, while Plotnikov’s theory addresses a dimerization stabilized by HLGAGs. As we shall see, the trimolecular complex of HLGAG, FGF and FGFR is probably stabilized by numerous interactions between each member.

Early models of the HLGAG-FGF-FGFR complex proposed that the stoichiometry consisted of only one FGF molecule cross-linking two FGFRs with or without the participation of HLGAGs. Pantoliano et al. (1994) put forward a model in which single FGF and HLGAG molecules formed a bridge between two FGFR molecules resulting in receptor dimerization. Alternatively, Springer et al. (1994) identified high-affinity (Tyr245, Tyr103, Leu140, Met147) and low-affinity (Lys110–Trp114) FGF binding sites on FGF, and, based on the bivalent nature of FGF, proposed that a single FGF molecule could cross-link two FGFRs. However, while both of these theories contained parts of the picture, they did not account for the participation of HLGAG-mediated FGF dimerization and oligomerization in FGF activation.

An alternative model of Spivak-Kroizman et al. (1994a) proposed that HLGAGs promote the formation of FGF dimers that in turn cross-link FGFRs (see Fig. 4). This model relied on the one-to-one interaction between FGF and FGFR shown by isothermal titration calorimetry, and the fact that HLGAGs can bind several FGF monomers. In this model HLGAGs cross-link FGFRs by using FGFs as adaptors. Unfortunately, the Spivak-Kroizman model did not explain the essential HLGAG-FGF interaction in receptor dimerization (Kan et al. 1993).

Within the past year three new, very similar, models have been proposed to explain the HLGAG-FGF-FGFR complex (Fig. 5). Venkataraman et al. (1999), Plotnikov et al. (1999) and most recently, Stauber et al. (2000) have independently proposed models in which a 2 FGF:2 FGFR dimer is stabilized by the addition of an HLGAG. In these models each FGFR in the dimer binds one FGF, and the complex itself is stabilized by HLGAG binding across a canyon formed by the FGF-FGFR pairs. In each of the FGF-FGFR pairs, IgII and IgIII both wrap around a single FGF molecule: IgII binding at Springer’s high affinity binding site (see above) and IgIII binding at the low affinity site (Venkataraman et al. 1999) or with other amino acids (Plotnikov et al. 1999, Stauber et al. 2000). Together, these pairs form a highly positive canyon at the IgII-FGF interface into which a single HLGAG can bind, thus placing minimal size restrictions on the HLGAG such that it must span both pairs in order to dimerize receptors. In addition, the extracellular domains of each FGFR stabilize the dimer by direct interactions, probably at the linker region between IgII and IgIII.

These three groups differ on a few other possible interactions. For example, Plotnikov et al. (1999) also have the dimer stabilized by one FGF binding not only to its own...
Figure 4  Spivak-Kroizman and coworkers' model for FGFR activation. HLGAGs oligomerize FGFs, which in turn cross-link FGFRs. (Modified from Spivak-Kroizman et al. 1994a.)

Figure 5  Simplification of the model of Venkataraman et al. (1999) and Plotnikov et al. (1999) for FGF-FGFR-HLGAG interaction and receptor dimerization. (Modified from Venkataraman et al. 1999.)
FGFR’s IgII, but also to the IgII in the adjoining pair. However, all three models take into account the interaction between HLGAGs and both FGFs and FGFRs, as well as the numerous interactions between FGFs and FGFRs themselves.

**FGFR signal transduction**

As we described above, the activated tyrosine kinase receptor recruits target proteins of the signaling cascade to its cytoplasmic tail and modifies them by phosphorylation. One way these recruited target proteins may be localized to the activated receptor is through the interaction between their Src-homology 2 (SH2) domains and specific phosphotyrosine residues on the activated receptor (Pawson 1995). These SH2-containing proteins may be substrates for receptor-mediated phosphorylation themselves, or they may function as adaptor proteins to recruit other target proteins. Tyrosine kinase receptors generally propagate signal transduction by phosphotyrosine-induced conformational changes in their target proteins resulting in activation of various catalytic activities.

**Structure of the FGFR cytoplasmic domain**

Most studies of FGFR-mediated signal transduction have been carried out using FGFR-1 as the prototypical FGFR. The signaling pathways from different FGFRs are probably quite similar owing to the high degree of homology at the amino acid level between different receptor types (Johnson & Williams 1993). In addition, Raffioni et al. (1999) have shown, by using chimeric receptors comprised of the cytoplasmic domains of FGFR-1, FGFR-3 and FGFR-4 linked to the extracellular domain of the PDGF receptor, that the principle difference between FGFRs in this model is the strength of tyrosine kinase activity, not any differences in target proteins (Raffioni et al. 1999).

There are seven tyrosine residues in the cytoplasmic tail of FGFR-1 that can be substrates for phosphorylation: Tyr<sup>463</sup>, Tyr<sup>583</sup>, Tyr<sup>585</sup>, Tyr<sup>653</sup>, Tyr<sup>654</sup>, Tyr<sup>730</sup> and Tyr<sup>766</sup>. Tyr<sup>653</sup> and Tyr<sup>654</sup> are important for the catalytic activity of the activated FGFR and are essential for signaling (Mohammadi et al. 1996) (see Fig. 6). Tyr<sup>766</sup> has been shown to bind the SH2 domain of phospholipase C-gamma (PLC<sub>γ</sub>) and is necessary for FGFR activation of PLC<sub>γ</sub> (Mohammadi et al. 1991). However, the other tyrosines can be mutated to phenylalanine residues, which are not substrates for auto-phosphorylation, without loss of mitogen activated protein (MAP) kinase (MAPK)-activity and mitogenic signaling in rat L-6 fibroblasts (Mohammadi et al. 1996), putting their roles in FGFR signal transduction in question.

It is interesting to note that a 90-kDa phosphoprotein has been observed associated with the adaptor molecule Grb2 following activation of both the wild-type and phenylalanine-mutated receptors. This suggests that FGFR signaling may

---

**Figure 6** Signaling through the cytoplasmic domain of FGFR. Symbols for HLGAG and FGF as in Fig. 5.

---

"Powers et al: FGFs and FGF signaling"
not rely only on the phosphotyrosine-SH2 pathway, an idea we will explore in more detail below.

The PLCγ signaling pathway
Activated PLCγ cleaves phosphatidylinositol-4,5-bisphosphate to inositol trisphosphate (IP3) and diacylglycerol (DAG). In turn, IP3 facilitates the release of calcium stores from the endoplasmic reticulum while DAG and calcium activate PKC. PLCγ was identified as a 150-kDa phosphoprotein associated with FGFR following ligand-dependent activation (Burgess et al. 1990), and this association is due to binding between the SH2 domain of PLCγ and Tyr463 of FGFR-1 (Mohammadi et al. 1991). Two groups independently mutated this tyrosine to phenylalanine, showing that this residue is essential for phosphatidylinositol hydrolysis (Mohammadi et al. 1992, Peters et al. 1992). However, mutation of Tyr463 did not affect FGFR-mediated mitogenesis, neuronal differentiation (Spivak-Kroizman et al. 1994b), or mesoderm-induction in a Xenopus animal cap model (Muslin et al. 1994). This implies that either PLCγ signaling is redundant with respect to mitogenesis and differentiation, or that the PLCγ pathway is important for some other function of FGFR signaling. Although the PLCγ pathway is not directly involved in cell motility (Langren et al. 1998), it may be involved in some other form of cytoskeletal alteration as the actin-binding protein profilin participates in PLCγ signaling (Goldschmidt-Clermont et al. 1991).

The Src signaling pathway
Src is a non-receptor tyrosine kinase that may link FGFR signaling to cortactin (Zhan et al. 1993), a focal adhesion-associated protein that binds filamentous actin (Wu et al. 1991b). This connection would provide an alternate pathway to that of PLCγ for FGFR-mediated cytoskeletal alterations. However, there are conflicting reports concerning the interaction of Src and FGFR. Zhan et al. (1994) found a direct interaction by immunoprecipitation with recombinant FGFR-1. On the other hand, Langren et al. (1995) saw no direct interaction and instead proposed that, as the Tyr463 to Phe463 mutant had high levels of phosphorylated Src, the PLCγ pathway inhibits Src activity.

Crk-mediated signaling
Crk is an SH2/SH3-containing adaptor protein which may link FGFR to the downstream signaling molecules Shc, C3G and Cas, which may in turn propagate a mitogenic signal from FGFR. Larsson et al. (1999) have shown that Crk binds via its SH2 domain to Tyr463 of the activated FGFR. Signaling through Crk has no effect on cell motility, yet endothelial cells expressing FGFR-1 with a phenylalanine substitution at Tyr463 failed to proliferate and the activity of both Erk2 and Jun kinase was suppressed. These results are in contradiction to those of Mohammadi et al. (1996), who determined that Tyr463 was not important for mitogenesis. Perhaps these differences are reflective of differences in FGFR signaling intrinsic to different cell types, as Mohammadi and coworkers used fibroblasts while Larsson and coworkers’ results were seen in endothelial cells.

The SNT-1/FRS2 signaling pathway
As mentioned above with studies of tyrosine-mutated FGF receptors, both the wild-type and the mutant receptor lacking all non-catalytic tyrosine residues have been shown to phosphorylate a novel 90-kDa protein, suggesting the existence of an alternative pathway to that of phosphotyrosine recruitment of SH2-containing proteins. This 90-kDa protein was independently identified as SNT-1 (Wang et al. 1996) or FRS2 (Kouhara et al. 1997) by two separate groups who both showed that SNT-1/FRS2 linked FGFR activation to the Ras/MAPK signaling pathway important for growth factor-induced cell-cycle progression. Activation of SNT-1/FRS2 recruits the adaptor protein Grb-2/Sos that in turn recruits Ras to the FGFR complex (Kouhara et al. 1997). In addition to associating with Grb-2, activated FRS2 also binds the protein tyrosine phosphatase Shp2 (Ong et al. 2000). Ong et al. (1997) have shown through co-immunoprecipitation that Shp2 associates with both FRS2 and the dock protein Gab-1. SNT-1/FRS2 is localized to the inner leaflet of the cell membrane by myristylation and interacts with FGFR-1 at amino acids 407-433 of the juxtamembrane region (Xu et al. 1998). In addition to linking FGFR signaling to the Ras/MAPK pathway, Lim et al. (1999) have shown recently that SNT-1/FRS2 can link FGFR activation to atypical protein kinase C isotypes, although the role this may play in mitogenesis or chemotaxis has yet to be characterized.

Interestingly, Ong et al. (2000) have shown that FRS2 is constitutively associated with FGFR1, independent of receptor activation. Nerve growth factor (NGF) receptors also utilize FRS2 in their signaling pathways; however association of FRS2 with NGF receptors is dependent on receptor activation. Consequently, FGFR1 may regulate NGF signaling by sequestering FRS2 from liganded NGF receptor.

Thus FGFRs mediate signal transduction by at least two independent pathways. First, FGFRs utilize the traditional SH2-linked pathway joining FGFR directly to PLCγ and Crk, and probably indirectly to Src. Secondly, FGFR is linked to SNT-1/FRS2 through an interaction at the juxtamembrane domain. Regulation of this second pathway has yet to be determined, as it seems to function independently of receptor phosphorylation, although this pathway appears at least superficially analogous to that of the insulin receptor and the insulin receptor substrate (IRS)-1 (Yenush & White 1997).
Through these, and perhaps other, yet to be defined pathways, FGFRs mediate the diverse effects of FGFs.

**Biological function of FGFs**

**Angiogenesis and wound healing**

The well-characterized role of FGF-1 and FGF-2 as fibroblast and endothelial cell growth factors (Folkman & Shing 1992) suggests that a significant biological function of FGFs is as positive regulators of angiogenesis. We will discuss FGFs as factors promoting tumor angiogenesis in the later section dealing with FGF signaling in cancer; however, here we will focus on the normal biological role of FGFs. Angiogenesis plays a significant biological role in wound healing and exogenous application of FGF-2 has been found both to promote skin wound healing in healing-impaired db/db mice (Tsuboi & Rifkin 1990) and to promote healing of infarcted myocardium following ischemic insult in both canine (Yanagisawa-Miwa _et al._ 1992) and porcine (Watanabe _et al._ 1998) models.

Wound repair progresses in four phases: inflammation, contraction, repair and regeneration. During the initial inflammatory response, a fibrin- and fibronectin-rich exudate containing numerous inflammatory cells and platelets invades the site of injury. Next, myofibroblasts, that have probably differentiated from pericytes or mesenchymal stromal cells, act to contract the wound, reducing the area to be repaired. The chief hallmark of the repair phase is the formation of granulation tissue, a richly vascularized connective tissue. Granulation tissue is characterized by the migration of endothelial cells and fibroblasts through a network of noncollagenous extracellular matrix resulting in the formation of new capillaries. Late repair is characterized by the deposition of collagen and the organization of the newly formed blood vessels. During the last phase of wound healing, regeneration, the lost epithelial cells are replaced as appropriate.

There is evidence to suggest that FGFs may play a role in at least three of the four phases of wound repair: inflammation, repair and regeneration. FGFs are stored not only in the extracellular matrix itself, but also in endothelial cells (McNeil _et al._ 1989) and fibroblasts (Werner _et al._ 1991). As mentioned above, the release of FGFs from these cells during wound repair may in fact be stimulated by creation of the wound itself. McNeil _et al._ (1989) have shown that various growth factors are released by mechanically wounded endothelial cells and have proposed that mechanical force is both a stimulus and a mechanism for FGF-2 release from endothelium. Of course, there is probably also some other signal for FGF release from endothelium and the stroma, as angiogenesis is not always due to a mechanical injury.

**FGFs in inflammation**

The role of FGFs in inflammation is supported by the localization of FGF-1 to the synovium of inflammatory arthritic joints (Sano _et al._ 1990) and to allografts showing the histological morphology of chronic allograft rejection (Zhao _et al._ 1993, 1995). The inflammation of arthritis and chronic rejection is characterized by a proliferation of lymphocytes. Production of interleukin-2, a powerful lymphocyte growth factor, has been shown to be stimulated by FGF-1 (Byrd _et al._ 1999), suggesting that FGFs, along with other factors, can induce the migration of inflammatory cells. FGFs may also play a role in the initial phase of wound repair by regulating platelet production, as platelets are also important constituents of the inflammatory response. FGF-4 has been shown to stimulate the proliferation of megakaryocyte progenitor cells (Konishi _et al._ 1996) and FGF-2 knockout mice have abnormalities in their serum platelet levels (Zhou _et al._ 1998).

**FGFs in repair**

The potential role of FGFs in the repair phase is obvious considering the powerful proliferative effects they have on endothelial cells and fibroblasts. Another important role of FGFs in the repair phase may be the facilitation of endothelial cell migration by regulation of proteolysis and adhesion molecules. FGF-2 has been shown to induce the urokinase-type plasminogen activator (uPA) gene in both endothelial cells (Gualandris & Presta 1995) and fibroblasts (Besser _et al._ 1995). uPA is a serine protease that converts the zymogen plasminogen to plasmin, a trypsin-like protease which cleaves, among other substrates, the fibrin deposited by initial clot formation. uPA can be localized to the cell surface by means of the uPA receptor, resulting in a pericellular zone of fibrinolysis (Werb 1997), and facilitating the migration of endothelial cells through the fibrin clot.

FGF-2 may also facilitate endothelial cell migration during the repair phase of wound healing through regulation of cell-surface adhesion molecules, most notably the αVβ3 integrin complex. Expression of the αVβ3 integrin complex on the surface of human microvascular endothelial cells is increased by treatment with FGF-2 (Sepp _et al._ 1994). The αVβ3 integrin complex, also known as the vitronectin receptor, mediates endothelial cell binding to extracellular components such as vitronectin and fibrinogen. In addition, expression of the αVβ3 integrin complex can also localize matrix metalloproteinases to the surface of endothelial cells providing another mechanism for the creation of a pericellular zone of fibrinolysis in addition to that mediated by uPA (Brooks _et al._ 1996).

**FGFs in regeneration**

Evidence for a potential role of FGFs in the final phase of wound healing, regeneration, comes from studies of renal
tubule repair following chemically induced proximal tubule damage. By means of in situ hybridization, Ichimura et al. (1996) have localized expression of FGF-7 to interstitial cells and FGFR-2(IIIb), a specific FGF-7 receptor isoform, to the tubular epithelium. This segregation of receptor and ligand expression suggests that FGFs, most notably FGF-7, may facilitate epithelial regeneration by means of a paracrine loop, with stromal cells releasing FGF-7 and the target epithelial cells expressing the appropriate receptor. Interestingly, Ichimura et al. (1996) also noted that the regeneration of renal tubules closely resembles the late stages of kidney development, in particular the differentiation of epithelium.

**FGFs in development**

FGFs play a role in development even prior to implantation, as FGF-signaling induces cell division of embryonic and extraembryonic cells of the mouse embryo starting as early as the fifth cell division (Chai et al. 1998). FGFs also seem to play a significant role in gastrulation, the formation of the three germ layers. FGFs have been shown to be mesoderm-inducing factors in *Xenopus*, as FGF-3 and FGF-4 are capable of inducing mesoderm derived from *Xenopus* animal pole cells in animal cap experiments (Paterno et al. 1989). The temporal and spatial localization of FGF-5 mRNA in pluripotent embryonic ectoderm and cells forming the three primary germ layers during gastrulation implicates FGF-5 as a regulatory factor of gastrulation (Hebert et al. 1991). In mouse embryos, FGF-8 is required for cells that have undergone an epithelial-mesenchymal transition to move away from the primitive streak (Sun et al. 1999). In FGF-8 knockout mice this failure to migrate results in the absence of embryonic mesoderm- and endoderm-derived tissues, as well as a disturbance in the patterning of the prospective neuroectoderm.

FGFs have also been shown to be relevant in organogenesis, particularly in that of the nervous system, the lung and limbs. FGF-8 is important in midbrain development (Crossley et al. 1996a) and cell patterning of the neural plate (Ye et al. 1998), while FGF-3 plays an important role in induction of the inner ear (Represa et al. 1991). FGF-10 plays a key role in lung development (Sekine et al. 1999) by triggering branching and differentiation of lung epithelium (Warburton et al. 1999). However, the most fully characterized role of FGFs is in limb development.

**FGFs in limb development**

FGFs have been shown to play a significant role in limb development in chick and mouse model systems. Normal limb development begins as the protrusion of a limb bud composed of lateral plate mesoderm and its covering ectoderm (Martin 1998). The mesenchymal cells in the limb bud will eventually differentiate to form the skeletal elements and connective tissues of the limb, while muscles are formed by cells that migrate into the developing limb from the somites. As the limb bud elongates, it forms recognizable skeletal elements which form from proximal to distal. Outgrowth and patterning of the developing limb has been found to depend on three distinct signaling centers. One of these is the apical ectodermal ridge (AER), a thickening of the ectoderm that runs anterior to posterior on the tip of the limb bud. The AER is chiefly responsible for proximal to distal development through signaling with FGF family members. A second, the zone of polarizing activity (ZPA), is in the mesenchyme at the posterior margin of the limb bud and is responsible for anterior–posterior axis determination through signaling with the sonic hedgehog (*Shh*) gene. And the third, the ectoderm at the limb tip which is not part of the AER, the so-called non-ridge ectoderm, is responsible for dorsal–ventral patterning through signaling with the *Wnt7a* gene.

The signals from the AER, ZPA and non-ridge ectoderm act on undifferentiated mesenchyme within the limb bud, the so-called ‘progress zone’. The progress zone remains at the tip of the developing limb under the ectoderm and the cells in the progress zone proliferate as a result of signals from the AER resulting in the elongation of the limb bud. As the limb bud elongates, the progress zone advances as well, leaving cells behind which terminally differentiate as skeletal elements of the limb. The time of exit from the progress zone is the key determinant of whether the mesenchymal cells will form proximal or more distal structures (Summerbell et al. 1973). Thus, cells in the progress zone are exposed to signaling from three distinct sources resulting in proximal–distal, anterior–posterior and dorsal–ventral patterning.

**FGFs in induction of limb buds**

FGFs play an important role in limb bud induction. Cohn et al. (1995) showed that beads soaked in FGF-1, -2 or -4 and placed in the flanks of chick embryos induce the formation of ectopic limb buds which can develop into almost normal limbs. It is remarkable that a single growth factor is sufficient to induce the development of a limb and this is indicative of the key role FGFs play in limb bud induction as well as in maintenance of limb development. The normal source of the limb induction signal has been identified as the intermediate mesoderm (IM) which lies between the lateral plate mesoderm and the somites and is composed of nephrogenic mesoderm (NM) and the Wolffian duct (WD) (Geduspan & Solorsh 1992). Crossley and coworkers have shown that FGF-8 is expressed in the developing limb bud and in the NM, and that its expression in the NM may be due to an uncharacterized signal from the WD (Crossley & Martin 1995, Crossley et al. 1996b). Thus, limb bud induction seems to occur as a result of a signal from the WD, which in turn triggers FGF-8 expression in the NM. FGF-8 is then capable...
of acting on the lateral plate mesoderm and inducing limb bud formation.

**FGFs in proliferation of developing limb**

FGFs also play a key role in the established limb bud as the proliferative signal from the AER. The dependence of limb development on an intact apical ectodermal ridge has been known since 1948, when Saunders showed that removal of the AER terminated any further limb development (Saunders 1948). The application of FGF-4-soaked beads to the exposed mesenchyme following apical ectodermal ridge removal led to essentially normal limb development (Niswander et al. 1993), showing that FGF-4 is sufficient to replace the AER. However, Fallon et al. (1994) showed that FGF-2-soaked beads are also sufficient to replace the AER and, in addition, FGF-2 is the only detectable FGF in chick limb bud extracts, suggesting that FGF-2 is the prime candidate for the chick limb bud AER signal. These observations have led developmental biologists to two key functions of the FGF produced by the AER. First, FGF stimulates proliferation of cells in the progress zone, leading to limb bud elongation and a pool of cells from which skeletal elements can differentiate. Secondly, FGF maintains sonic hedgehog (Shh) expression in the zone of polarizing activity (Vogel & Tickle 1993, Crossley et al. 1996b). In addition, Shh can act on cells in the AER to maintain FGF-4 expression, resulting in a positive-feedback loop between the FGFs and Shh (Laufer et al. 1994). The interaction between the apical ectodermal ridge and the zone of polarizing activity through FGFs and sonic hedgehog confirms a molecular link between proximal–distal and anterior–posterior patterning (see Fig. 7).

**Knockout studies of FGFs**

The key role FGFs seem to play in angiogenesis and development might lead one to conclude that animals lacking particular FGFs would manifest serious abnormalities. This is true with the fgf-4−/− (Feldman et al. 1995) and fgf-8−/− (Sun et al. 1999) mutations which are embryonic lethal, while fgf-10−/− mice die at birth due to insufficient lung development (Sekine et al. 1999). On the other hand, fgf-2−/− and fgf-6−/− mice are not only viable, but are phenotypically indistinguishable from wild-type animals by gross examination (Fiore et al. 1997, Ortega et al. 1998). This observation is probably due to regulatory redundancies in processes controlled by fgf-2 and fgf-6: thus while certain FGFs may contribute to various processes, this does not mean that they are necessary for proper regulation, as other family members may be able to substitute.

![Figure 7](https://example.com/figure7.png)

*Figure 7* Possible roles of FGFs in induction, initiation and maintenance of limb development. (Modified from Martin 1998.)
This is almost certainly the case with angiogenesis, as $fgf-2^{-/-}$ mice demonstrate only a three-day lag over wild-type animals in excisional skin wound repair (Ortega et al. 1998), no alteration in the dynamics of vessel repair following mechanical injury (Zhou et al. 1998) and a comparable level of retinal neovascularization in a murine model of oxygen-induced ischemic retinopathy (Ozaki et al. 1998). On the other hand, control of vascular tone does seem to be affected in the $fgf-2^{-/-}$ mice. They display decreased vascular smooth muscle contractility (Zhou et al. 1998) and an impaired baroreceptor reflex as elicited by isoproterenol, a $\beta$-adrenergic agonist (Dono et al. 1998). As a result of these two defects, $fgf-2^{-/-}$ mice have a lower mean arterial pressure than wild-type animals. This suggests that whatever role FGF-2 may play in angiogenesis, some other factor can replace it, while with regulation of vascular tone, other factors cannot compensate for the loss of FGF-2.

One other area where FGF-2 seems to play an indispensable role is in cortical development. $fgf-2^{-/-}$ mice display a reduction in neuronal density in the motor cortex, neuronal deficiencies in the cervical spinal cord and ectopic neurons in the hippocampal commissure (Ortega et al. 1998). The neuronal density deficit is probably due to a loss of an FGF-2-induced increase in the number of rounds of division of cortical progenitors (Vaccarino et al. 1999). Micro-injection of FGF-2 at embryonic day 15.5 into the cerebral ventricles of $fgf-2^{-/-}$ mice results in an 18% increase in cortical volume and an 87% increase in the number of neurons in the adult cortex.

While it is possible that the lack of profound phenotypic defects in $fgf-2^{-/-}$ mice is due to compensation by other FGF family members, FGF-1 does not seem to be the active factor in this regard. Miller et al. (2000) have recently shown that $fgf-1^{-/-}$ and $fgf-2^{-/-}$ double knockout mice displayed similar mild phenotypic defects as $fgf-2^{-/-}$ single knockout mice, suggesting that FGF-1 is not the factor that compensates for a lack of FGF-2.

**Thalidomide: limb defects and cancer**

The discussion of the role of FGFs in limb development is particularly relevant in light of the newly found use of thalidomide as an antiangiogenic drug in the treatment of cancer. Thalidomide was first introduced as a sedative in the 1950s, but fell out of use when, in 1961, McBride and Lenz described a link between limb defects in babies and maternal thalidomide use (McBride 1961, Lenz 1962). The most prominent congenital defect following fetal exposure to thalidomide metabolites (the parent drug is itself harmless) is phocomelia, or shortening of the limbs, suggesting that thalidomide metabolites interfere with proximal-distal patterning in the developing limb bud. The mechanism for this interference seems to be the action of thalidomide metabolites in blocking proliferation of limb bud mesenchyme in the progress zone (Stephens 1988). The result is that cells in the progress zone do not leave to form more proximal structures and only distal structures are formed from the limb bud.

The teratogenic metabolites of thalidomide also seem to have antiangiogenic properties. D’Amato et al. (1994) showed that orally administered thalidomide is an inhibitor of angiogenesis induced by FGF-2 in a rabbit cornea micropocket assay, and given intraperitoneally, thalidomide significantly inhibits FGF-2- and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in a mouse model (Kenyon et al. 1997). In addition, thalidomide has recently been shown to inhibit endothelial cell proliferation itself in vitro (Moreira et al. 1999). Taken together, these results suggest that thalidomide metabolites may interfere with FGF signaling; however, the precise nature of this interference remains unknown.

**FGF signaling in cancer**

Following release into the extracellular environment, polypeptide growth factors such as the FGFs bind cell surface receptors that, in turn, can activate many signal transduction cascades. These signal transduction pathways will then activate various genetic programs through the concerted regulation of transcription factors, stimulating cell growth by promoting cell cycle progression and inhibiting pathways of cell death. All components of this pathway, from the polypeptide growth factors to the transcription factors, are potential oncoproteins. That is, loss of regulation at any step can result in the driving of those downstream components to promote cell growth beyond control, thus resulting in neoplastic growth. Here we will discuss alterations in both FGFs themselves as well as the FGF receptors and the potential roles such alterations may have in cancer. We will also briefly examine the genetic programs activated by FGF signaling. Finally, we will discuss the evidence for a role of FGF signaling in steroid hormone-dependent cancers.

**FGFs in cancer**

*Overexpression of secreted FGFs*

As there are no documented activating mutations in FGFs themselves, the clearest mechanism by which FGFs may contribute to unregulated cell proliferation is by overexpression; thus potential sources for secreted FGFs are the most important target of investigation. Within epithelial tumors there are, in the simplest terms, only two possible sources of FGFs: the tumor cells themselves or the surrounding stromal cells. FGFs may be released from either of these sources and they may also act on either of these sources; consequently FGFs may act in an autocrine or a
paracrine manner or both. There are at least three possibilities: first, FGFs may simply be overexpressed and secreted by the tumor cells themselves; secondly, FGFs may be secreted by the stromal cells in response to a signal from the tumor cells; and thirdly, FGFs may be secreted by the tumor in response to a signal from non-transformed cells.

An example of the first possibility, that of FGF secreted by the tumor cells as an autocrine growth factor and a paracrine angiogenic factor, has been shown to occur in the case of human gliomas (Takahashi et al. 1992). FGF-2 mRNA has been shown to be expressed in over 94% of human gliomas (Takahashi et al. 1990); however, the FGF-2 protein has not been detected in normal brain by immunohistochemistry (Takahashi et al. 1992). The expression of FGF-2 has also been shown positively to correlate with the degree of malignancy and vascularity in human gliomas (Takahashi et al. 1992). Because FGF receptors are expressed on both the tumor cells and non-tumor cells (Takahashi et al. 1991), it is not surprising that FGF-2 can act as an autocrine growth factor on the tumor itself, as well as act to promote angiogenesis in the surrounding stroma.

The second possibility, that of FGFs secreted by non-transformed stromal cells in response to a signal from the tumor, is illustrated with FGF-5 in pancreatic cancer. FGF-5 mRNA has been localized by in situ hybridization to cancer-associated macrophages and fibroblasts, yet it is not detected in fibroblasts in normal pancreatic tissue (Kornmann et al. 1997). Fibroblasts can be induced to express FGF-5 by epidermal growth factor (EGF), PDGF and transforming growth factor-α (TGFα) (Werner et al. 1991) and all of these factors are overexpressed in human pancreatic cancer tissues (Korc et al. 1992, Ebert et al. 1995). This suggests that FGF-5 is secreted as a paracrine growth factor by the non-transformed cells in the tumor stroma in response to signaling factors present in the tumor. Such a paracrine signaling pathway would need to be completed by signaling through FGFRs in response to FGFs. By overexpressing a truncated dominant-negative FGFR-1, Wagner et al. (1998) showed that two human pancreatic cell lines, Panc-1 and MIA PaCa-2, are dependent on signaling through FGFR-1 for activation of the MAP kinase cascade, increased proliferation, and, most importantly, increased tumor formation in vivo in response to FGFs.

In a converse mechanism to that illustrated with FGF-5 in pancreatic cancer, the production of FGF-2 by the transformed cells in Kaposi’s sarcoma seems to be a result of signals from the non-transformed stromal cells. The transformed cells in Kaposi’s sarcoma, so-called ‘spindle cells’, have been shown to produce and release FGF-2 in response to tumor necrosis factor-α (TNFα), IL-1 and interferon-γ (INFγ) (Samaniego et al. 1998). Kaposi’s sarcoma is characterized by an inflammatory cell infiltrate and TNFα, IL-1 and INFγ are all released by these activated T-lymphocytes (Samaniego et al. 1998). In this situation the inflammatory cells probably release mediators which cause the tumor cells to oversecrete FGF-2.

Release of sequestered FGFs from the extracellular matrix

Another possibility for disregulation of FGF signaling in cancer as a result of increased availability of FGFs may be due to the mobilization of FGFs from the ECM. There are currently two models for the release of FGFs from this ECM reservoir: enzymatic cleavage of ECM components, by proteases or heparanases, resulting in the release of FGFs, or binding to a carrier protein, which can then deliver FGFs to their receptors (see Fig. 8). Numerous studies have investigated the release of soluble FGFs from the ECM by

Figure 8 Three possible mechanisms for the mobilization of stored FGFs from the ECM. (Modified from Rak & Kerbel 1997.)
the digestion of the glycosaminoglycan portion of HLGAGs through the activity of heparanases (Vlodavsky et al. 1988, Bashkin et al. 1989, Moscatelli 1992), and recently the mammalian gene for heparanase has been isolated independently by Vlodavsky et al. (1999) and Hulett et al. (1999). They have shown expression of this gene at the mRNA and protein levels in metastatic human and rat cell lines as well as in samples of human breast, colon and liver carcinomas. Interestingly, expression of the heparanase gene seems to correlate with invasive phenotype of several human breast cancer cell lines: the non-metastatic cell line MCF-7 does not express the heparanase gene, the moderately metastatic cell line MDA-MB 231 showed moderate levels of heparanase activity and gene expression, while the highly metastatic cell line MDA-MB 435 had high levels of heparanase activity and gene expression. In addition, low metastatic murine T-lymphoma and melanoma cells transfected with the heparanase cDNA developed the ability to metastasize to lung and liver, while the parent cells did not display this phenotype. The ability of heparanases to release bound stores of FGFs, which can then trigger angiogenesis, is consistent with the observed role of heparanases in promoting metastasis. Thus, by regulating expression of heparanases some tumors may be able to mobilize FGFs from the ECM.

The studies of Saksela & Rifkin (1990) provide a good in vitro example of the regulation of FGF release by proteolysis of the protein backbone of HLGAGs. They have shown that plasmin releases [125I]FGF-2 bound to the ECM secreted by bovine capillary endothelial (BCE) cells in culture. This mechanism may allow for a positive-feedback loop, as FGF-2 is capable of increasing plasminogen-activator activity in BCE cells (Saksela et al. 1987). Plasminogen added to a culture of BCE cells with the addition of FGF-2 results in an increased release of labeled FGF-2 from the ECM (Saksela & Rifkin 1990). Thus, FGF-2 release can be increased by the stimulation of proteolytic activity in the pericellular environment through the activity of FGF-2 itself.

A second mechanism for the regulation of FGF release from the ECM may be through the activity of a carrier protein that shuttles FGFs from their site of storage to FGF receptors. The FGF-binding protein (FGF-BP) is a 17-kDa protein originally isolated from the human epidermoid carcinoma cell line A431 which binds FGF-1 and FGF-2 in a non-covalent, reversible manner (Wu et al. 1991a). Transfection of the human adrenal adenocarcinoma cell line SW-13, which expresses FGF-2, with an expression vector for FGF-BP results in a malignant phenotype as determined by colony formation in soft agar and the growth of tumors in nude mice (Czubayko et al. 1994). FGF-BP is known to be tightly regulated during development: high levels have been detected in skin and intestine perinatally, yet it is downregulated in adult tissues (Kurtz et al. 1997). However, FGF-BP is upregulated in adult skin during early stages of carcinogenesis as well as in squamous cell carcinoma (SCC) and some colon carcinoma cell lines (Czubayko et al. 1997, Kurtz et al. 1997). Depletion of FGF-BP in human SCC (ME-180) and colon carcinoma (LS174T) cell lines through the use of FGF-BP targeting ribozymes decreases growth and angiogenesis in a xenograft tumor model (Czubayko et al. 1997). These observations have led to the possibility that regulation of FGF-BP may be just as important as direct regulation of FGF production because of the ability of FGF-BP to mobilize the FGF reservoir. In fact, retinoids may act to inhibit growth of SCC cell lines in vitro through the down-regulation of FGF-BP levels (Liaudet-Coopman et al. 1997) and phorbol ester promotion of skin cancer may be through a stimulatory effect at the FGF-BP promoter (Harris et al. 1998).

FGF receptors in cancer

Disregulation of FGF signaling as a result of alterations at the level of the receptor has been shown to occur in four possible forms: inappropriate expression, point mutations, splice variations and genomic alterations. While not all of these alterations are associated with human cancer, we will, nevertheless, briefly consider each one of these possibilities in turn. FGFRs have also been shown to be overexpressed in comparison to normal tissues by immunohistochemistry of brain (Morrison et al. 1994), breast (Yoshimura et al. 1998), prostate (Giri et al. 1999), thyroid (Shingu et al. 1998), melanoma (Ahmed et al. 1997) and salivary gland (Myoken et al. 1996) tumor samples. With most of the examples of overexpression of FGFRs in cell lines and tumor samples, one or more FGF is often also expressed, creating the possibility for autocrine FGF signaling. Causes for such overexpression are largely uncharacterized: however the role of chromosomal translocation described below is certainly one such mechanism.

There is a wealth of data supporting the existence of activating point mutations of FGFRs, but such mutations have only been found in developmental defects such as skeletal dysplasias (Webster et al. 1996) and craniosynostotic syndromes (Mangasarian et al. 1997, Chun et al. 1998, Gripp et al. 1998). In these cases, point mutations may occur in the extracellular, transmembrane or kinase domains and all such mutations result in ligand-independent activation of the FGFRs (Neilson & Friesel 1996). While such mutations would seem to be possible mechanisms leading to cancer development, none has been shown to be involved in human cancer. An alteration in post-transcriptional processing has also been shown to occur with FGFR-3, but as is the case with point mutations, this alteration has an unknown role in human cancers. A splice variant of FGFR-3 has been reported in breast epithelial cells that is missing exons 7 and
8, which code for the transmembrane domain, yet has an intact kinase domain and is located in the nucleus (Johnson et al. 1995). While the nuclear localization of some members of the FGF family themselves raises the possibility of a completely novel autocrine signaling pathway in the nucleus, the role of nuclear localization of this FGFR-3 splice variant is unclear.

Finally, gene rearrangements have also been shown to lead to ligand-independent activation of FGFRs. A constitutively active form of FGFR-2 has been found in a rat osteosarcoma cell line (Lorenzi et al. 1996). In this cell line, chromosomal rearrangement leads to the alteration of the C-terminus of the FGFR-2 protein as a result of fusion to a novel gene designated FGFR activating gene 1 (FRAG1). The FGFR-2-FRAG1 fusion protein seems to form constitutive dimers resulting in autophosphorylation of the FGFR-2 kinase domains and activation of the FGF signaling pathway. Another chromosomal translocation in human myeloid cells has also been shown to result in activation of the FGF signaling pathway. Human myeloid cells containing the t(4;14)(q16.3;q22.3) translocation have been shown to have increased expression of FGFR-3 resulting in the activation of an FGF autocrine loop, as determined by blocking antibodies to FGF-4, a principle ligand of FGFR-3 (Otsuki et al. 1999).

**Genetic programs of tumor growth**

FGFs may activate genetic programs which promote cell growth by at least one of three general mechanisms: first, as mitogens for the tumor cells themselves, secondly, by promoting angiogenesis to supply a growing tumor, and thirdly, by inhibiting apoptosis and allowing tumor cells to continue to grow beyond normal constraints.

**FGFs as mitogenic factors**

FGF-1 and FGF-2 were initially isolated based on their ability to stimulate incorporation of [H]thymidine in 3T3 fibroblasts, suggesting that they are powerful mitogenic factors. However, it is important to separate the concept of adding an exogenously produced protein to that of overexpressing the gene itself. While FGF-1 and FGF-2 are potent mitogens in their own right, overexpressed fgf-1 and fgf-2 cDNAs are only powerful transformants for fibroblasts if a signal sequence is inserted in the 5′ region of the cDNA; otherwise they are only weakly transforming (Basilico & Moscatelli 1992). This suggests that inefficient secretion may limit the potential of FGF-1 and FGF-2 to transform cells efficiently. This also suggests that a mutation which allowed the efficient secretion of FGF-1 or FGF-2 might be oncogenic; however, as mentioned above, such a mutation has never been observed.

fgf-3 was initially identified as a gene which is overexpressed as a result of MMTV insertion upstream of its promoter (Dickson et al. 1984). However, it is uncertain how important this overexpression actually is in mammary tumor development, as overexpression of FGF-3 mRNA is not powerfully transforming by itself (Basilico & Moscatelli 1992), probably, like FGF-1 and FGF-2, because of inefficient secretion (Kiefer et al. 1993). However, fgf-3 is consistently expressed in tumorigenic, but not non-tumorigenic, clones of human colon cancer cell lines (Galdemard et al. 1995), suggesting that it may be necessary, although not sufficient, for some tumors.

fgf-4 was isolated by screening genes from human cancers themselves for a transforming effect on 3T3 fibroblasts (Sakamoto et al. 1986, Delli Bovi & Basilico 1987), attesting to its mitogenic capability. In addition, perhaps because FGF-4 is efficiently secreted, it has been shown to transform fibroblasts by establishing an autocrine loop (Delli Bovi et al. 1987, Talarico & Basilico 1991). Interestingly, an amino-terminal truncated FGF-4 mutant has been shown to bind its receptor more tightly than the full length protein (Bellotta et al. 1993); however, this form has not been shown to be more oncogenic.

fgf-5 was identified by screening tumor cell lines for sequences capable of transforming 3T3 cells (Zhan et al. 1988). In fact, the fgf-5 gene was identified because the juxtaposition of a retroviral transcriptional enhancer element resulted in FGF-5 overexpression (Zhan et al. 1988). Like FGF-4, FGF-5 is also efficiently secreted, suggesting that FGF-5-induced transformation is due to overexpression.

**FGFs as angiogenic factors**

FGF-1 and FGF-2 are well-defined pro-angiogenic molecules (Folkman & Shing 1992). In addition, FGF-3 and FGF-4 have been shown to induce angiogenesis in vivo in chick chorioallantoic membrane assays (Wellstein et al. 1992, Costa et al. 1994, Yoshida et al. 1994). Two other FGFs, FGF-5 and FGF-7, also seem to possess pro-angiogenic properties. FGF-5 co-localizes with VEGF in epiretinal membranes (Schneeberger et al. 1997), is expressed by bovine epithelial cells in vitro (Keithahn et al. 1997), and its expression in choroidal neovascular membranes is associated with age-related macular degeneration (Kitaoka et al. 1997); however it remains to be definitively identified as an angiogenic factor. FGF-7, although widely thought of as an epithelial cell mitogen, has been shown to induce in vivo neovascularization in the rat cornea (Gillis et al. 1999). To date, however, the role of all the other FGFs as angiogenic factors remains undefined.

**FGFs as antiapoptotic factors**

Bcl-2 is an antiapoptotic protein initially found to be overexpressed in human follicular lymphomas (Tsujimoto et al. 1985). The possibility that FGF-2 may participate in the regulation of apoptosis through bcl-2 was first suggested by...
Murai et al. (1996) because neutralizing antibodies to FGF-2 were found to induce apoptosis in human glioma cell lines overexpressing FGF-2, and this apoptosis could be inhibited by the overexpression of bcl-2. FGF-2 was shown to upregulate expression of bcl-2 in B cell chronic lymphocytic leukemic cell lines resulting in a delay in fludarabine-induced apoptosis (Konig et al. 1997). In addition, FGF-1 has been shown to upregulate bcl-2 expression in the human SH-SY5Y neuroblastoma cell line (Raguenes et al. 1999). There appears to be a different story in other cancer cell lines, as FGF-2 has been shown to downregulate expression of bcl-2 and actually promote apoptosis in MCF-7 cells (Wang et al. 1998). Clearly, the exact role of FGFs in apoptosis remains to be fully elucidated.

**FGFs and steroid hormones in cancer**

Epithelium whose growth is regulated by endogenous steroid hormones can give rise to tumors that, like the parent tissue, are also dependent on steroid hormones for growth. However, as these tumors progress, they may become independent of steroid hormones for growth, limiting the effectiveness of anti-hormonal therapies for their treatment. This is particularly important with breast or prostate cancer, in which the tumor may progress from a steroid-dependent to a steroid-independent phenotype, rendering it unresponsive to hormonal therapies. An attractive hypothesis to explain the progression to steroid independence is that the tumor acquires the ability to constitutively express autocrine growth factors previously induced by the steroid hormone itself. There is evidence in some cancer models that particular FGFs may function as autocrine growth factors capable of conferring steroid independence.

Such a function has been demonstrated in SC-3 cells, a murine cell line derived from the mouse mammary carcinoma, Shionogi 115, whose growth is markedly increased by treatment with androgens. Koga et al. (1995) demonstrated that this androgen-dependent growth is mediated by the simultaneous induction of FGF-8 and FGFR-1. Sato et al. (1993) showed that blockade of FGF-8 activity by antisense oligonucleotides blocks androgen-induced growth of SC-3 cells (Sato et al. 1993), suggesting that FGF-8 plays a key role in mediating the effect of androgens on this cell line. In addition, expression of the FGF-8 cDNA in androgen-dependent cells facilitates their conversion to an androgen-independent phenotype, yet is not in itself sufficient to induce it (Koga et al. 1995), suggesting the important role of simultaneous expression of the receptor in order to complete the autocrine loop.

An FGF-mediated autocrine loop has also been demonstrated in human breast cancer. Either FGF-1 or FGF-4 overexpression in the estrogen-dependent human breast cancer cell line MCF-7 induces an estrogen-independent phenotype as determined by tumor growth and metastasis in nude mice (McLeskey et al. 1993, Kern et al. 1994). As this alteration is not due to changes in estrogen receptor levels (McLeskey et al. 1998), it is likely that the FGF autocrine loop acts downstream from an estrogen signal. In order to determine if FGF functions as an autocrine growth factor in mediating the estrogen-independent growth of FGF-1 overexpressing cells in nude mice, these cells were transfected with an FGFR-1 vector encoding a truncated dominant negative FGF receptor (Zhang et al. 1998). The expression of the dominant negative receptor inhibited the ability of the FGF-1 overexpressing cells to form tumors in the absence of estrogen in ovarietomized nude mice. This suggests that FGF-1 acts as an autocrine growth factor in order to promote estrogen-independent tumor formation in this model. Importantly, disruption of the FGF autocrine loop did not abolish the formation of tumors in mice supplemented with estrogen or tamoxifen, perhaps because of a synergy between estrogen-promoted mitogenicity and a paracrine FGF-1 effect.

The situation in prostate appears to be slightly more complicated. Isolated epithelial and stromal cells from normal rat prostate and androgen-responsive tumor models are themselves androgen-independent for growth (McKeeman et al. 1984). Instead, their growth is dependent on various polypeptide growth factors, suggesting that the function of androgen on prostate epithelium may be indirectly mediated by other growth factors (McKeeman et al. 1984). Co-culture of prostate epithelial and stromal cells revealed androgen-sensitive growth by the epithelial cells, while the stromal cells were unresponsive (Yan et al. 1992). These observations can be explained by the finding that FGF-7 is expressed by prostate stromal cells in response to androgen treatment, but not by prostate epithelial cells (Yan et al. 1992). Because prostate epithelial cells express FGFR-2(IIIb) (Miki et al. 1992), the receptor specific for FGF-7, this suggests that in the normal prostate, androgens regulate epithelial cell growth by inducing FGF-7 expression in the stromal cells. FGF-7 may then act as a paracrine growth factor on the epithelial component owing to its expression of FGFR-2(IIIb). Recently, FGF-10 has also been identified as a potential paracrine mediator of the androgen signal in the prostate (Lu et al. 1999).

The progression of androgen-dependent to androgen-independent prostate cancer may be due to yet another additional FGF signaling pathway. Injection of a mixture of stromal and epithelial cells from a rat prostate tumor model into rats resulted in the formation of non-malignant, differentiated, slowly growing tumors (Yan et al. 1993). However, in the absence of stromal cells, the tumors were malignant, poorly differentiated and grew rapidly (Yan et al. 1993). This independent and aggressive growth was accompanied by two important changes in gene expression which appear to establish an autocrine signaling loop. First, the cells switched their expression of FGFR-2 from the IIIb
isoform to the IIIc isoform, which binds FGF-2 but not FGF-7, and secondly, they began to express FGF-2 itself (Yan et al. 1993). This suggests that in prostate cancer, androgen-dependent growth relies on FGF-7, and perhaps FGF-10 also, as a paracrine growth factor, yet the switch to androgen independence may result from the activity of FGF-2 as an autocrine growth factor.

**Conclusion**

With all the information of the FGF family and its receptors described above, we can see a basic mechanism for FGF action. FGF is produced by cells, enters the extracellular milieu and eventually binds to and activates cell surface receptors on target cells. Receptor binding triggers a signal transduction cascade mediated by protein phosphorylation, culminating in alterations in gene expression. However, one aspect of this mechanism is still unclear, namely what happens between FGF secretion and receptor activation. We know that FGFs are secreted through either the classical secretory pathway, or, in the case of FGF-1, -2 and -9, by some as yet uncharacterized ER-Golgi-independent pathway. Upon release, FGF quickly becomes associated with the HLGAGs in the ECM. This association may afford FGF protection from proteolysis, as well as creating a local reservoir of growth factors. However, the association of FGF with ECM HLGAGs is a sticky point, as it is unclear how FGF can then localize to the cell surface and activate the FGFR. There are two mutually compatible mechanisms for how FGF may activate the FGFR from its association with the ECM. First, FGF bound to the ECM may not actually be sequestered and may be available to cell surface receptors. If a cell comes in contact with this FGF-primed ECM, the signaling pathway can be activated, thus allowing for a strict spatial regulation of FGF signaling. A second mechanism is that this store of FGFs can be rapidly mobilized through proteolysis, the activity of heparanases, or the activity of a sequestered binding protein, FGF-BP. Proteolysis and heparanolysis are attractive mechanisms because they allow the possibility that a large amount of FGF can be released in conjunction with HLGAGs. This is important because HLGAGs are required components of the activated receptor complex along with FGFs. The FGF-BP mechanism is also attractive in the light of our unpublished observation that FGF-2 binds well to FGF-BP or to HLGAGs but not to both at the same time. Thus FGF-BP may pick up FGF from the ECM and carry it to the cell surface where it is dropped off to cell surface HLGAGs. In turn, the cell surface HLGAGs could present FGF to the FGFR and participate in the complex as well. It is possible that each of these mechanisms is operating at different times and in different situations. With the first mechanism, FGF may signal from the ECM to promote chemotaxis and cell migration during development. The second model may explain FGF signaling during wound repair and tumor angiogenesis, as numerous proteolytic enzymes and heparanases are activated during these processes. And with the FGF-BP model, we have a mechanism for FGF signaling that may be appropriate whenever finely tuned regulation of FGF signaling is required. Clearly, tumor development may be facilitated by the disregulation of these mechanisms for FGF release through the inappropriate expression of proteases, heparanases or FGF-BP. Future studies of the regulation of these mechanisms will be required to elucidate further the role of FGF signaling in cancer.

**References**


Antoine M, Reimers K, Dickson C & Kiefer P 1997 Fibroblast growth factor 3, a protein with dual subcellular localization, is targeted to the nucleus and nucleolus by the concerted action of two nuclear localization signals and a nucleolar retention signal. *Journal of Biological Chemistry* 272 29475–29481.


Bashkin P, Docotrow S, Klagsbrun M, Svahn CM, Folkman J & Vlodavsky I 1989 Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by

188


Byrd VM, Ballard DW, Mille GG & Thomas JW 1999 Fibroblast growth factor-1 (FGF-1) enhances IL-2 production and nuclear translocation of NF-κB in FGF receptor-bearing Jurkat T cells. Journal of Immunology 162 5853–5859.


Crossley PH & Martin GR 1995 The mouse Fgfl gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo. Development 121 439–451.


Delli Bovi P, Curatola AM, Kern FG, Greco A, Ittmann M & Basilico C 1987 An oncogene isolated by transfection of
Kaposi’s sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell 50 729–737.


Feige J-J & Baird A 1989 Basic fibroblast growth factor is a substrate for protein phosphorylation and is phosphorylated by capillary endothelial cells in culture. PNAS 86 3174–3178.


Florkiewicz RZ & Sommer A 1989 Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. PNAS 86 3978–3981.


Galdenmard C, Briston O & Lavialle C 1995 The proto-oncogene FGF-3 is constitutively expressed in tumorigenic, but not in non-tumorigenic, clones of a human colon carcinoma cell line. Oncogene 10 2332–2342.


Gospodarowicz D & Cheng J 1986 Heparin protects basic and acidic fibroblast growth factor from inactivation. Journal of Cellular Physiology 125 475–484.


Guan J-L, Machamer CE & Rose JK 1985 Glycosylation allows by profillin via free access...
generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt’s lymphomas. Cell 52 185–195.


Jackson A, Friedman S, Zhan X, Engleka KA, Forough R & Maciag T 1992 Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells. PNAS 89 10691–10695.


Kiefer P & Dickson C 1995 Nucleolar association of fibroblast growth factor 3 via specific sequence motifs has inhibitory effects on cell growth. Molecular and Cellular Biology 15 4364–4374.


Powers et al: FGFs and FGF signaling

XFGF-20, in Xenopus laevis. Biochemical and Biophysical Research Communications 261 756–765.


Lobb RR 1988 Thrombin inactivates acidic fibroblast growth factor but not basic fibroblast growth factor. Biochemistry 27 2572–2578.

Lorenzi MV, Hori Y, Yamanaka R, Sakaguchi K & Miki T 1996 FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement. PNAS 93 8956–8961.


McWhirter JR, Goulding M, Weiner JA, Chun J & Murre C 1997 A novel fibroblast growth factor gene expressed in the
developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. *Development* **124** 3221–3232.


Moenner M, Chevallier B, Badet J & Barrittaud D 1986 Evidence and characterization of the receptor to eye-derived growth factor I, the retinal form of basic fibroblast growth factor on bovine epithelial lens cells. *PNAS* **83** 5024–5028.


Moscatelli D 1987 High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. *Journal of Cellular Physiology* **131** 123–130.


Ong SH, Lim YP, Low BC & Guy GR 1997 SHP2 associates directly with tyrosine phosphorylated p90 (SNT) protein in FGF-stimulated cells. *Biochemical and Biophysical Research Communications* **238** 261–266.


Otsuki T, Yamada O, Yata K, Sakaguchi H, Schlessinger J & Lax I 1999 Expression of fibroblast growth factor and FGF-receptor family genes in human myeloid cells, including lines possessing t(4;14)(q16.3;q32.3) and FGFR translocation. *Cell Growth and Differentiation* **3** 561–563.


Sakula O & Rifkin DB 1990 Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by...


Powers et al: FGFs and FGF signaling


Webster MK, D’Avis PY, Robertson SC & Donoghue DJ 1996 Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. *Molecular and Cellular Biology* **12** 4081–4087.


Yayon A, Klagesbrun M, Esko JD, Leder P & Ornitz DM 1991 Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. *Cell* 64: 841–848.


